NCT03110575Phase 3Terminated

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Study sponsor: Tonix Pharmaceuticals, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2018-07-27Actual
Enrollment · participants190Actual
Source updated2025-02-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview